Skip to main content

Table 5 DPPR, MPR, Lu item, MARS-5, EQ-5D-5L utility and EQ-VAS scores pre- and post-session 1

From: A non-randomised pilot study of the Solutions for Medication Adherence Problems (S-MAP) intervention in community pharmacies to support older adults adhere to multiple medications

  Number of patients Pre-session 1 median (IQR) 95% confidence intervals for pre-session 1 median Post-session 1, median (IQR) 95% confidence intervals for post-session 1 median Za Effect size (r)b
Primary outcome: dispensing data measures (DPPR, MPR)   
DPPR (%) 44 85.2 (72.0-96.7) 73.9-92.9 93.8 (84.8-97.8) 86.8-96.7 −3.80 −0.41
MPR (%) 44 93.8 (82.8-100.0) 88.9-97.5 94.6 (87.8-97.8) 89.7-97.5 −1.28 −0.14
Primary outcome: self-reported adherence   
Lu item (%) 36 80 (60-80) 60-80 100 (80-100) 80-100 −3.45 −0.41
MARS-5 total 25 22 (20-23.5) 21-23 24 (24-25) 24-25 −3.12 −0.44
Secondary outcome: EQ-5D-5L    
EQ-5D-5L- Utility index 30 0.73 (0.52-0.84) 0.53-0.80 0.74 (0.58-0.84) 0.65-0.77 −0.91 −0.12
EQ-5D-5L-VAS 35 75 (50-83) 60-80 75 (60-85) 65-80 −0.12 −0.01
  1. Key: DPPR daily polypharmacy possession ratio; MARS-5 Medication Adherence Report Scale; MPR medication possession ratio; IQR interquartile range
  2. aTest statistic for Wilcoxon signed-rank test
  3. bEffect size (r) calculated using r = Z/√N; where Z is the z score for the Wilcoxon signed-rank test and N is the total number of observations. −0.1 indicates a small effect size, −0.3 indicates a medium effect size and −0.5 indicates a large effect size